Abstract: New propanone derivatives, the pharmacologically allowable salts thereof, their manufacturing process and pharmaceutical composition containing at least one of them as the active ingredient.

Abstract: Novel quinolylacetic acid compounds of the formula (I): ##STR1## wherein R.sub.1 is a member selected from the group consisting of hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms, and a lower alkyl group having 1 to 4 carbon atoms substituted with an aromatic group having a substituent;R.sub.2 is a member selected from the group consisting of hydrogen atom and a lower alkyl group having 1 to 4 carbon atoms;R.sub.3 is a member selected from the group consisting of hydrogen, a halogen atom, an alkyl group having 1 to 8 carbon atoms, and an alkenyl group having 2 to 8 carbon atoms;R.sub.4 and R.sub.5, carpable of cyclization, are each a member selected from the group consisting of hydrogen atom and a lower alkyl group having 1 to 4 carbon atoms;R.sub.

Abstract: Heterocyclic compounds comprising the formula (I): ##STR1## wherein: R.sub.1, R.sub.2, R.sub.4 and R.sub.5 each are hydrogen or a lower alkyl group;R.sub.3 is hydrogen, a halogen, an alkyl group, a haloalkyl group, an alkoxy group, an alkenyl group, an alkenyloxy group, an aryl group, an aryloxy group, an acyl group or a nitro group;and the broken line connotes a single or double bond at the C.sub.3 -C.sub.4 position, provided that when the broken line connotes a single bond, R.sub.3 is other than hydrogen; and pharmaceutically acceptable salts thereof,exhibiting antiinflammatory, antipyretic and analgesic action.

Abstract: New propanone derivatives, useful for treating allergic diseases, the pharmacologically allowable salts thereof, their manufacturing process and pharmaceutical composition containing at least one of them as the active ingredient.

Abstract: The present invention is directed to an iron complex used in treatment of iron-deficiency anemia. The complex is formed by reacting a reactive polyiron (III) olated compound with dextrin and at least one hydroxycarboxylic acid. A dextrin-hydroxycarboxylato-polyiron (III) olated complex is produced. The reaction product contains substantially no free iron. Iron concentration is between about 35 and 47%. The complex can be administered non-orally.The compound of the subject invention has advantages over prior art compounds. Specifically, the subject complex has a high iron content, is thermally stable, and can be preserved. It may be administered intravenously without accumulating in the blood of an animal or damaging its tissue. No serious side effects result from use of the subject complex.

Abstract: Trioxopteridine derivatives of the formula ##STR1## , wherein R.sub.1 is a normal alkyl group having 0 to 6 hydroxyl groups and R.sub.2 is hydrogen or a normal lower alkyl group having 0 to 5 hydroxyl groups, are prepared by catalytically hydrogenating a 6-substituted-5-nitro-2,4-dioxopyrimidine to give a 6-substituted-5-amino-2,4-dioxopyrimidine, and then reacting the latter compound with a compound of the formula R.sub.2 --A--COOR.sub.3, wherein R.sub.3 is hydrogen, lower alkyl, an alkali metal or an alkaline earth metal and A is carbonyl or a group of the formula ##STR2## wherein R.sub.4 is lower alkyl. The resulting trioxopteridine derivatives have analgesic and antiphlogistic properties and are therefore useful as pharmaceutical medicaments.

Abstract: Trioxopteridine derivatives of the formula ##SPC1##, wherein R.sub.1 is a normal alkyl group having 0 to 6 hydroxyl groups and R.sub.2 is hydrogen or a normal lower alkyl group having 0 to 5 hydroxyl groups, are prepared by catalytically hydrogenating a 6-substituted-5-nitro-2,4-dioxopyrimidine to give a 6-substituted-5-amino-2,4-dioxopyrimidine, and then reacting the latter compound with a compound of the formula R.sub.2 --A--COOR.sub.3, wherein R.sub.3 is hydrogen, lower alkyl, an alkali metal or an alkaline earth metal and A is carbonyl or a group of the formula ##EQU1## wherein R.sub.4 is lower alkyl. The resulting trioxopteridine derivatives have analgesic and antiphlogistic properties and are therefore useful as pharmaceutical medicaments.